Comparisons of groups based on the statuses of IDH, 1p19q, and TERT revealed that TERT mutation bestows better outcomes in gliomas with TERT mutant/IDH mutation/1p19q co-deletion, but poorer survival in GBM with TERT mutant/IDH mutation without 1p19q co-deletion [63]. This evidence concerns the gene IDH2 and central nervous system cancer.